In an interview about the efficacy of COVID-19 vaccines, Richard Marlink, the director of Rutgers Global Health Institute, responds to public opinion about the differences among vaccines that are authorized or in the pipeline for use in the United States. The following is an excerpt from the story published by ROI-NJ: When the news that Johnson & Johnson had completed Phase 3 of its clinical trial and that its one-shot vaccine would soon be available finally was released Friday morning, there was unbridled excitement. It would be a game-changer, many said. To read the full story.
Recent Posts
- Join NJ ACTS Special Populations Core Seminar Series on 4/30 at 1pm
- NJACTS Community Engagement Core COVID-19 Resources
- Long-Acting Opioids May Be Unnecessary in Study of Total Knee Replacement.
- Predicting Loneliness Through Online Digital Footprints.
- $265K Awarded to NJIT Researchers Via New Jersey Health Foundation Grants.
Categories
- News (2,125)
- Publication (1)